PL2903691T3 - Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit - Google Patents

Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit

Info

Publication number
PL2903691T3
PL2903691T3 PL13844154T PL13844154T PL2903691T3 PL 2903691 T3 PL2903691 T3 PL 2903691T3 PL 13844154 T PL13844154 T PL 13844154T PL 13844154 T PL13844154 T PL 13844154T PL 2903691 T3 PL2903691 T3 PL 2903691T3
Authority
PL
Poland
Prior art keywords
diagnosing
methods
inflammatory bowel
bowel disease
treating inflammatory
Prior art date
Application number
PL13844154T
Other languages
English (en)
Inventor
Mary Keir
Gaik Wei Tew
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2903691T3 publication Critical patent/PL2903691T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
PL13844154T 2012-10-05 2013-10-04 Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit PL2903691T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261710656P 2012-10-05 2012-10-05
US201361860422P 2013-07-31 2013-07-31
EP13844154.8A EP2903691B1 (en) 2012-10-05 2013-10-04 Methods for diagnosing and treating inflammatory bowel disease
PCT/US2013/063384 WO2014055824A1 (en) 2012-10-05 2013-10-04 Methods for diagnosing and treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
PL2903691T3 true PL2903691T3 (pl) 2019-10-31

Family

ID=50435452

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13844154T PL2903691T3 (pl) 2012-10-05 2013-10-04 Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit

Country Status (17)

Country Link
US (2) US9873742B2 (pl)
EP (1) EP2903691B1 (pl)
JP (3) JP6449161B2 (pl)
KR (1) KR101850591B1 (pl)
CN (1) CN104870056A (pl)
AR (1) AR092908A1 (pl)
AU (1) AU2013326921C1 (pl)
BR (1) BR112015007528A2 (pl)
CA (1) CA2884368C (pl)
ES (1) ES2738305T3 (pl)
HK (1) HK1213522A1 (pl)
IL (2) IL237650B (pl)
MX (1) MX2015003932A (pl)
PL (1) PL2903691T3 (pl)
RU (1) RU2015112024A (pl)
SG (1) SG11201502548YA (pl)
WO (1) WO2014055824A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015024856A2 (pt) * 2013-03-27 2018-04-17 Genentech Inc métodos de determinação ou de monitoramento
EP3122377A4 (en) 2014-03-27 2018-03-14 F.Hoffmann-La Roche Ag Methods for diagnosing and treating inflammatory bowel disease
JP2018504584A (ja) * 2014-12-02 2018-02-15 ネステク ソシエテ アノニム 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法
MX2017010336A (es) * 2015-02-26 2017-12-20 Genentech Inc Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
RU2018113694A (ru) * 2015-09-17 2019-10-17 Эмджен Инк. Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23
CN108780088A (zh) * 2015-11-06 2018-11-09 维蒂卡实验室公司 在伴侣动物中检测炎症标志物和治疗炎性病症的方法
EP4235173A3 (en) 2016-02-02 2023-09-13 Maximus Diagnostic Technologies LLC Assessment of intestinal barrier function to improve treatment of inflammatory bowel disease
RU2668790C2 (ru) * 2017-03-20 2018-10-02 Ольга Евгеньевна Давыдова Способ сбора биопсийного материала стенки толстой кишки для микробиологического исследования у пациентов с язвенным колитом
JP7365358B2 (ja) 2018-04-12 2023-10-19 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
WO2020113164A1 (en) * 2018-11-30 2020-06-04 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
CN110373457B (zh) * 2019-06-20 2023-03-14 镇江市第一人民医院 一种用于溃疡性结肠炎诊断的mRNA标志物及其应用
TW202332675A (zh) 2019-10-16 2023-08-16 美商莫菲克醫療股份有限公司 抑制人類整合素α4β7
CN111477275B (zh) 2020-04-02 2020-12-25 上海之江生物科技股份有限公司 微生物目标片段中多拷贝区域的识别方法、装置及应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4256833A (en) 1979-01-08 1981-03-17 Majid Ali Enzyme immunoassay for allergic disorders
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
CA2046909A1 (en) 1989-03-21 1990-09-22 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
ES2112838T5 (es) 1989-07-19 2004-09-01 Connetics Corporation Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AU668423B2 (en) 1992-08-17 1996-05-02 Genentech Inc. Bispecific immunoadhesins
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
AU2582897A (en) 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
AU2001259142C1 (en) 2000-04-25 2006-11-23 Biogen Idec Inc. Intrathecal administration of rituximab for treatment of central nervous system lymphomas
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
MX2007002675A (es) * 2004-09-03 2007-06-11 Genentech Inc Antagonistas anti-beta7 humanizados y usos para los mismos.
JP2008524230A (ja) * 2004-12-15 2008-07-10 エヌエスエイビーピー ファウンデイション，インコーポレイテッド 癌治療における予後及び予測マーカーの同定及び使用
US8940493B2 (en) * 2006-06-02 2015-01-27 Veridex Llc Circulating tumor cell assay
US20100255508A1 (en) * 2008-05-16 2010-10-07 Thomas Richard Gelzleichter Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
EP2419177A1 (en) * 2009-04-17 2012-02-22 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
EP2576824A2 (en) * 2010-06-07 2013-04-10 Roche Diagnostics GmbH Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
KR20130091746A (ko) * 2010-07-19 2013-08-19 에프. 호프만-라 로슈 아게 췌장암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커
MY189494A (en) * 2011-03-31 2022-02-16 Genentech Inc Methods of administering beta7 integrin antagonists

Also Published As

Publication number Publication date
JP6720130B2 (ja) 2020-07-08
JP2016501510A (ja) 2016-01-21
JP2018085989A (ja) 2018-06-07
AU2013326921A1 (en) 2015-04-02
US9873742B2 (en) 2018-01-23
US20150307611A1 (en) 2015-10-29
SG11201502548YA (en) 2015-04-29
BR112015007528A2 (pt) 2018-09-04
AU2013326921B2 (en) 2017-07-13
EP2903691B1 (en) 2019-05-22
US11091551B2 (en) 2021-08-17
AR092908A1 (es) 2015-05-06
ES2738305T3 (es) 2020-01-21
IL237650B (en) 2020-03-31
CN104870056A (zh) 2015-08-26
EP2903691A4 (en) 2016-06-01
EP2903691A1 (en) 2015-08-12
IL269529A (en) 2019-11-28
WO2014055824A1 (en) 2014-04-10
HK1213522A1 (zh) 2016-07-08
RU2015112024A (ru) 2016-11-27
IL237650A0 (en) 2015-04-30
KR20150058270A (ko) 2015-05-28
MX2015003932A (es) 2015-07-23
AU2013326921C1 (en) 2018-01-18
US20180346576A1 (en) 2018-12-06
KR101850591B1 (ko) 2018-04-19
CA2884368A1 (en) 2014-04-10
JP2020120656A (ja) 2020-08-13
CA2884368C (en) 2022-01-18
JP6449161B2 (ja) 2019-01-09

Similar Documents

Publication Publication Date Title
IL269529A (en) Methods for diagnosing and treating inflammatory bowel disease
HK1219512A1 (zh) 用於診斷和治療炎性腸病的方法
HK1200933A1 (zh) 改善炎性腸病診斷的方法
EP2971127A4 (en) DIAGNOSTIC AND TREATMENT METHODS FOR INFLAMMATORY INTESTINAL DISEASE
IL276516A (en) Methods for diagnosing and treating inflammatory bowel disease
EP2814514A4 (en) HISTIDYL-ARNT SYNTHETASES FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
ZA201304334B (en) Methods for diagnosing and treating eye-length related disorders
HK1221393A1 (zh) 不用結腸切除術治療炎性腸病的方法和組合物
ZA201408059B (en) Compositions and methods for the treatment of inflammatory bowel disease
HK1212220A1 (en) Antigens associated with inflammatory bowel disease
EP2569451A4 (en) METHOD AND DEVICES FOR DIAGNOSING MORBUS ALZHEIMER
IL229704A (en) Means and methods for diagnosing multiple sclerosis and causing its treatment
EP2879715A4 (en) METHOD AND KIT FOR A DARM PREPARATION
GB201223223D0 (en) Inflammatory bowel disease
HK1207581A1 (en) Constructs for diagnosing and treating inflammatory bowel diseases and colon cancer
HK1218249A1 (zh) 用於治療炎症性腸道疾病的化合物和方法
EP2928460A4 (en) METHODS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY SKIN DISEASES
HK1222400A1 (zh) 抗嗜酸細胞活化趨化因數抗體在治療炎症性腸病中的應用
ZA201307890B (en) Compositions and methods for treating diagnosing and monitoring disease
GB201211023D0 (en) Oligonucleotide probe set and methods for the diagnosis of inflammatory bowel disease
PL2870968T3 (pl) Leczenie klinoptilolitem zapalnych chorób jelit
EP2903514A4 (en) LUNG DIAGNOSIS DEVICES AND METHODS
GB201212964D0 (en) Diagnostic and prognostic methods